Veraxa Biotech AGNASDAQ: VRXA

VERAXA Biotech (NASDAQ: VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy

· Issued by Veraxa Biotech AG

Summary by 6ix AI

VERAXA Biotech, which develops antibody-based cancer therapies, gave a corporate and pipeline update on July 6, 2026 covering the first half of 2026. It plans to prioritize investment in its proprietary BiTAC portfolio, which includes four T-cell engager programs, while seeking to earn money from selected non-BiTAC programs to help fund future development.

Key details

  • The four BiTAC-based T-cell engager programs (antibodies designed to bring immune T cells to cancer cells) target solid tumors; the pipeline also includes two bispecific antibody-drug conjugate (ADC, an antibody linked to a drug) programs and two non-BiTAC assets available for partnering.
  • The goal is to bring lead BiTAC T-cell engager candidate VXA-102 to IND/CTA readiness, meaning ready to apply to regulators to start clinical trials, by early 2028.
  • Company executives cited strong industry interest in T-cell engager and ADC technologies. They said recent partnering discussions at the BIO International Convention and other scientific meetings reinforced confidence in the company's BiTAC platform and its potential to secure strategic collaborations.

What’s still pending

  • Bringing VXA-102 to IND/CTA readiness by early 2028 is a stated goal, not a completed step.
  • Selling or licensing selected non-BiTAC programs is something the company is seeking; no deal is reported.
  • No partnership or collaboration agreement is reported.

6ix AI wrote this summary from the release below and checked it against the release.

Featured Image

Austin, Texas, United States, July 6th, 2026, FinanceWire

VERAXA Biotech (NASDAQ: VRXA) provided a corporate and pipeline update highlighting progress during the first half of 2026, including continued advancement of its proprietary BiTAC(R) platform and growing interest from potential pharmaceutical partners. The company said its pipeline now includes four BiTAC-based T-cell engager programs targeting solid tumors, two bispecific antibody-drug conjugate ("ADC") programs and two non-BiTAC assets available for partnering. VERAXA said it plans to prioritize investment in its BiTAC portfolio while seeking to monetize selected non-BiTAC programs to help finance future development, with the goal of advancing lead BiTAC-TCE candidate VXA-102 to IND/CTA readiness by early 2028.

Company executives also cited strong industry interest in T-cell engager and ADC technologies, noting that recent partnering discussions at the BIO International Convention and other scientific meetings reinforced confidence in the company's differentiated BiTAC platform and its potential to secure strategic collaborations. VERAXA said it continues to refine both its pipeline and partnering strategy as it advances its next generation of cancer therapies.

To view the full press release, visit https://ibn.fm/xTF5q

About VERAXA Biotech AG

At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.

BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to VRXA are available in the company's newsroom at https://ibn.fm/VRXA

Contact
IBNwww.InvestorBrandNetwork.comEditor@InvestorBrandNetwork.com

Veraxa Biotech AG on 6ix

Earlier from Veraxa Biotech

Later from Veraxa Biotech

All Veraxa Biotech news releases